How does one approach maintenance treatment in transplant ineligible patients with newly diagnosed multiple myeloma?

IMROZ and BENEFIT trials are interesting in that they are billed as for transplant-ineligible patients, yet frail patients were excluded, so I don't think they give us the answer for how to maintain a frail patient. The best answer for a frail patient is, I believe, the MAIA trial, which gives DRD t...

Data from these two trials do not change practice from a maintenance standpoint. The regimen should be decided based on patient frailty and risk status, leaning towards 2 drugs for high risk and one for standard risk, frailty being the limiting factor for those with high risk where one drug may have...

Been using a quadruplet or a triplet regimen for patients with newly diagnosed myeloma who are not considered eligible for an autologous stem cell transplantation, it would typically contain an anti-CD38 monoclonal antibody along with lenalidomide with or without bortezomib. In these patients, I wou...

Maintenance remains a key element of upfront therapy in MM, particularly in transplant-ineligible MM patients who receive either triplet or quadruplet regimens. In the MAIA study (Facon et al., PMID 31141632 and Facon et al., PMID 40016302), patients in the DRd arm essentially transitioned to monthl...